Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Advaxis, Inc., (OTCBB: ADXS) ("Advaxis" or the "Company"), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.

“We are pleased to have the opportunity to present the final 12-month survival and other relevant data from our 110 patient trial of ADXS-HPV in recurrent/refractory cervical cancer at ASCO's annual meeting”

Abstract #5529, titled ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer, was selected for presentation at the Poster Discussion Session: Gynecologic Cancer to be held on June 2, 2013 from 8:00 - 11:30 a.m. This poster will describe updated safety, tumor response, and survival data from the ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin being conducted by Advaxis in India.

Abstract #TPS3121, titled A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265), was selected for presentation at the Developmental Therapeutics - Immunotherapy Trials in Progress General Poster Session to be held on June 3, 2013 from 8:00 -11:45 a.m. This poster will describe the trial design for the ongoing Phase 2 study being conducted by the Gynecologic Oncology Group (GOG) in the United States.

Abstracts will be released on www.asco.org at 6:00 PM on May 15, 2013.

"We are pleased to have the opportunity to present the final 12-month survival and other relevant data from our 110 patient trial of ADXS-HPV in recurrent/refractory cervical cancer at ASCO's annual meeting," commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. "ADXS-HPV immunotherapy offers the promise of an effective and well-tolerated treatment for cervical cancer that employs the patient's immune system to fight the cancer. We are encouraged by the interest that our colleagues in GOG have in joining our efforts to evaluate the potential of ADXS-HPV in cervical cancer, through the conduct of GOG-0265."